This two-day conference will serve as a platform to discuss compliance and transparency areas of key concern. Goal is to unravel compliance challenges, define and learn fair market value and develop a consistent, simple and transparent method and strategy for your company.
The ugly truth about being beautiful
Cosmetic testing that uses animals is notably controversial. Dripping chemicals into the eyes, shaving the fur and deliberate irritation to skin, long exposure to potential carcinogens or dangerous substances without pain relief drugs…
Even if not tested, products often include substances like animal fat, fish scales, hormones, stomach enzymes, gelatin, liver oil, animal gland steroids, wax and honey or even shark and turtle oil.
The European Union took a step forward in March 2013, when a new law was fully implemented and made it illegal to sell animal-tested cosmetics in Europe, even if the testing was done outside Europe. However, vivisection (experimentation on live animals) continues. 1,170,326 signatures were collected, but the initiative to stop vivisection was denied by the EU Commission.
Despite the remarkable progress that’s been made, ingredients used in cosmetics may still be tested on animals in the EU under REACH, the world’s largest chemical testing programme. Also testing on animals for household products continues. And when you Google cosmetic companies that still test on animals, around 330 names come up!
Scientists should follow the three Rs in order to reduce the impact of research on animals: Reduction, Refinement and Replacement. Reducing the number of animals used in experiments and refining the experiment in a way that the animal suffers as little as possible should be commonplace when they can't abstain from the use of animals. But the third “R” is the best way to go – replacement with alternative methods such as in-vitro testing, research with human volunteers or test tube methods.
Products in Europe that are not tested on animals carry the symbol of the “Leaping Bunny”. Take action, look for information, sign petitions and check what products you are buying. #becrueltyfree
Interested in this topic?
Project & Portfolio Management for Pharma and Biotech – EAST
For the upcoming Project and Portfolio Management for Pharma and Biotech Conference, Fleming presents a high-level meeting building on more than a decade of experience in running global Pharma PPM events worldwide.
Patient Adherence and Engagement
Discuss the issues of non-adherence with other stakeholders and find a solution together with the patients themselves.
Take a Good Look at the Future of Corporate Universities
There are four things corporate universities can do to avoid becoming irrelevant in the digital age.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?
With improved patient engagement to increased patient adherence
Chronic illnesses are commonly treated with the long-term use of medications. This treatment could be successful, however, its benefits are overshadowed by the fact that 50% of patients don't take their medications as prescribed. Reveal all the alarming numbers of non-adherence and learn how to decrease it with improved patient engagement.